Cerebell (CBLL) Q1 2026: Account Base Expands by 33 as Pediatric, Delirium Launches Broaden TAM
Cerebell’s Q1 marked a decisive expansion phase, with record new hospital accounts and the commercial launches of neonate, pediatric, and delirium solutions unlocking new revenue streams. High-margin execution and robust headband utilization signal operational leverage, while management’s guidance raise reflects confidence in both core and emerging markets. Attention now shifts to the pace of adoption in new indications and the sustainability of account productivity gains into 2027.
Summary
- Hospital Penetration Accelerates: Record net new account additions and expanded salesforce productivity signal durable demand.
- Platform Expansion Broadens Market: Neonate, pediatric, and delirium launches open new growth vectors and reinforce clinical leadership.
- Margin Resilience Amid Cost Pressures: Tariff mitigation and Vietnam sourcing support sustained high gross margins.
Business Overview
Cerebell develops and commercializes EEG-based brain monitoring systems for acute care settings, with a primary focus on seizure detection and expanding into delirium and stroke indications. Revenue is generated through a mix of product sales (headbands, monitors) and subscriptions (software, support), targeting hospitals, with a growing presence in both the Veterans Affairs (VA) and military hospital networks. The company’s platform approach aims to make EEG monitoring a “new vital sign,” and its major segments are acute seizure monitoring, pediatric/neonate solutions, and delirium diagnostics.
Performance Analysis
Q1 2026 delivered 29% year-over-year revenue growth, driven by both record net new hospital account additions and increased headband usage per account. The quarter saw 33 net new hospitals added, bringing the active base to 680, with notable momentum in the VA system following FedRAMP high authorization. Product and subscription revenues each grew 29% year-over-year, reflecting balanced expansion across both hardware and recurring software streams.
Gross margin held at 87%, demonstrating resilience despite elevated Chinese tariff costs, which were nearly fully offset by 2025 cost reduction initiatives. The company is transitioning sourcing to Vietnam, expected to further support high-margin levels in the back half. Operating expenses rose 36%, largely from commercial investments and a spike in litigation costs, while adjusted EBITDA loss remained relatively stable, underscoring disciplined expense management outside of non-recurring legal spend.
- Account Acquisition Momentum: Largest-ever quarter for new hospital adds, underpinned by a maturing and expanding sales team.
- Utilization Upside: Record headband usage per account, with best-practice sites using the system at triple the average rate.
- Margin Defense: Tariff headwinds nearly fully offset, with further relief expected from Vietnam manufacturing ramp.
Cash and equivalents of $141.2 million support the company’s objective to reach cash flow breakeven, while ongoing litigation remains a notable near-term cost headwind. The guidance raise for full-year revenue reflects continued confidence in both core and new business lines.
Executive Commentary
"Q1 was a strong quarter. We delivered revenue of $26.5 million, growing 29% year-over-year and 7% sequentially. Growth was driven by record headband utilization and our largest quarter of net new account additions. We also delivered 87% growth margin and expect to maintain growth margin in the high 80s range throughout 2026."
Jane Chow, Co-Founder and Chief Executive Officer
"As we move into the back half of 2026, we will begin shipping inventory sourced from our fully operational line in Vietnam, which is subject to lower tariff rates. Consequently, we feel confident in our ability to maintain gross margins in the high 80% range throughout 2026."
Scott Blumberg, Chief Financial Officer
Strategic Positioning
1. Core Seizure Market Penetration
Cerebell’s ambition to become the standard of care for seizure management in 6,000 U.S. hospitals is underpinned by a dual focus: adding new accounts and deepening utilization within existing ones. The salesforce expansion initiated in late 2024 is now bearing fruit, with over 85% of tenured new hires contributing to account growth and 100% generating purchase orders. The company’s VA and military hospital entry, enabled by FedRAMP high certification, broadens institutional reach and validates product-market fit in complex, security-sensitive environments.
2. Pediatric and Neonate Launches
The commercial rollout of neonate and pediatric seizure monitoring products marks a critical inflection, expanding the total addressable market (TAM) and reinforcing Cerebell’s clinical relevance. Early pilots at five hospitals converted to full implementation, with strong feedback on safety, ease of use, and economic benefits—such as reduced patient transfers and improved reimbursement retention. While initial revenue contribution is modest, these launches set the foundation for more meaningful impact in 2027 and beyond.
3. Delirium Solution and Platform Synergy
The activation of the first delirium pilot sites in April positions Cerebell as the only FDA-cleared provider in this $1 billion market. The delirium solution is not only a standalone revenue opportunity but also enhances the value proposition of the core seizure platform, with clinical evidence suggesting significant overlap in ICU populations. The company is leveraging ongoing pilots and a Vanderbilt Medical Center study to refine workflows, validate pricing, and build clinical evidence for broader adoption. A potential CMS new technology add-on payment (NTAP) could further accelerate uptake if finalized in August 2026.
4. Operational Leverage and Margin Management
Gross margin resilience is supported by proactive cost management, with the transition to Vietnam manufacturing expected to yield further relief from tariff-related headwinds. Management’s ability to nearly offset elevated costs through 2025 initiatives demonstrates operational discipline and supports the case for sustainable high-margin growth as the business scales.
5. Litigation and R&D Investment
Elevated G&A expense, driven by $5.6 million in IP litigation costs, is expected to moderate in the back half of 2026. R&D investments are fueling both platform enhancements and pipeline expansion, including the LVO stroke indication, which received breakthrough device designation in January. These investments are intended to secure long-term competitive advantage and reinforce Cerebell’s platform leadership.
Key Considerations
This quarter underscores Cerebell’s transition from a single-indication player to a multi-platform neurological monitoring leader, with execution momentum in both core and expansion markets. Investors should weigh the durability of salesforce productivity, the pace of adoption in new clinical settings, and the company’s ability to translate pilot traction into commercial scale.
Key Considerations:
- Salesforce Maturation Drives Growth: Over 85% of new sales hires with 12+ months tenure contributed to account growth, with more expected to reach productivity through 2026.
- Clinical and Economic Validation in Pediatrics: Neonate pilots converted to full launches, driven by strong safety, clinical buy-in, and reduced patient transfers.
- Delirium Market Entry Expands TAM: Early pilot activation and strong clinical interest support the platform’s move into a $1 billion new market.
- Seasonal Utilization Patterns: Q2 and Q3 typically see lower ICU census, but management expects growth initiatives to offset some of this seasonal moderation.
- Litigation Costs Nearing Peak: Elevated G&A from IP litigation is expected to decline after Q2, improving adjusted EBITDA trajectory.
Risks
Key risks include protracted IP litigation, which has spiked G&A expenses and could continue to disrupt near-term profitability. Adoption risk remains in new verticals, as pilot-to-commercial conversion timelines and reimbursement dynamics are still being validated. Seasonal fluctuations in ICU census may mask underlying account growth, and any delays in Vietnam supply chain transition could impact margin guidance. Competitive threats from new entrants or alternative technologies in neurological monitoring also warrant close watch.
Forward Outlook
For Q2 2026, Cerebell did not provide explicit quarterly guidance but reiterated seasonal moderation in utilization per account due to lower ICU census.
- Management expects sequential Q2 usage per account to decline, offset by ongoing new account additions and CAM-driven growth initiatives.
- Litigation expenses expected to remain elevated in Q2 before moderating in the back half.
For full-year 2026, management raised guidance:
- Total revenue now expected to range from $112 to $116 million, up from prior $111 to $115 million.
Management highlighted:
- Strong confidence in both account acquisition and increased utilization as core growth drivers.
- Potential for further upside from Vietnam inventory transition and NTAP reimbursement approval for delirium solution.
Takeaways
Cerebell is executing on a multi-pronged growth strategy, with record account expansion, robust margin defense, and a pipeline of new clinical indications that expand both TAM and competitive moat.
- Record Account Growth: Largest-ever net new hospital additions, underpinned by salesforce maturity and targeted system-level engagement, support durable growth trajectory.
- Platform Expansion Beyond Seizure: Neonate, pediatric, and delirium launches validate Cerebell’s strategy to become a comprehensive neurological monitoring provider, with early clinical and economic feedback supporting long-term adoption.
- 2027 and Beyond Watchpoint: The pace at which new indications convert from pilot to scaled revenue, and the sustainability of salesforce productivity, will be critical to sustaining high growth and margin leverage.
Conclusion
Cerebell’s Q1 2026 results reinforce its trajectory as a platform leader in neurological monitoring, with operational execution, expanding clinical footprint, and strategic investments positioning the company for sustained growth. The next phase will hinge on commercial scaling in new indications and operational discipline as litigation expenses recede.
Industry Read-Through
Cerebell’s expansion into pediatrics and delirium signals a broader industry shift toward integrated, multi-indication monitoring platforms in acute care. The company’s early success with system-level hospital sales and value-based economic arguments foreshadow a competitive landscape where clinical validation and workflow integration are paramount. Reimbursement innovation, such as NTAP approvals, will be a key catalyst for adoption across medtech peers. Operational discipline in margin management despite tariff volatility sets a benchmark for device makers navigating global supply chain shifts. Platform synergy and evidence generation are likely to become differentiators for neurological and critical care device companies aiming to expand their TAM and entrench their hospital footprint.